Rigel Pharmaceuticals Stock Price - RIGL

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Rigel Pharmaceuticals Inc RIGL NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.145 5.03% 3.025 3.05 2.87 2.89 2.88 14:58:07
Bid Price Ask Price Spread Spread % News
3.02 3.03 0.01 0.33% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
7,234 1,322,625 $ 2.95 $ 3,906,895 1,886,534 1.56 - 3.10
Last Trade Time Type Quantity Stock Price Currency
14:58:07 100 $ 3.025 USD

Rigel Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 507.02M 167.61M $ -70.48M -0.44 - 166.89M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Rigel Pharmaceuticals News

Loading Messages....

Latest RIGL Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RIGL Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.173.102.10012.804,431,1110.85539.4%
1 Month2.163.101.982.442,054,6940.86540.05%
3 Months2.303.101.972.311,488,2540.72531.52%
6 Months2.413.101.562.061,429,3210.61525.52%
1 Year2.103.101.562.171,427,4510.92544.05%
3 Years2.174.711.562.941,697,2610.85539.4%
5 Years2.185.201.562.991,348,0830.84538.76%

Rigel Pharmaceuticals Description

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken over all responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes Fostamatinib - ITP, Fostamatinib - AIHA, Fostamatinib - IgAN, BGB324 - Oral AXL Inhibitor, ATI-50001 & 50002 - JAK Inhibitors, DS-3032-MDM2 Inhibitor, THF-beta Inhibitors and AZD0449- Inhaled JAK Inhibitor.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.